Results

Total Results: 1,540 records

Showing results for "month".

1. Erythropoiesis-Stimulating-Agents-Utilization Research (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/pdf/erythropoiesis-stimulating-agents-utilization_research.pdf
   February 01, 2011 - , the month prior, and the month after (i.e., enrolled in a 3-month window). … month, at least one in the month prior, and at least one in the month after, if the beneficiary did … month prior. … and the month after (i.e., in a 3-month window). … month.

2. Data-Points-7-Tables1 (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/data-points-7-tables1.xls
   May 29, 2025 - 209.x 210.x to 229.x 230.x to 234.x 235.x to 238.x 239.x Biologic Response Modifiers ALDESLEUKIN 1 month … 19.84% 48.46% 39.84% 68.78% 13.50% - 33.33% 14.80% 36.10% 27.80% Biologic Response Modifiers BCG 1 month … - 4.71% 2.48% 13.27% 3.00% 8.48% 96.75% - 19.69% 3.68% 27.23% 5.65% Kinase Inhibitors ERLOTINIB 1 month … 83.90% 21.34% 6.19% 74.16% 5.28% 0.25% 27.61% 14.70% 28.13% 31.10% Kinase Inhibitors EVEROLIMUS 1 month … 28.13% 25.00% 92.61% 95.17% 4.55% 4.55% 27.27% 9.94% 24.43% 29.26% Kinase Inhibitors GEFITINIB 1 month

3. Data-Points-7-Tables (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/data-points-7-tables.xls
   May 29, 2025 - 209.x 210.x to 229.x 230.x to 234.x 235.x to 238.x 239.x Biologic Response Modifiers ALDESLEUKIN 1 month … 19.84% 48.46% 39.84% 68.78% 13.50% - 33.33% 14.80% 36.10% 27.80% Biologic Response Modifiers BCG 1 month … - 4.71% 2.48% 13.27% 3.00% 8.48% 96.75% - 19.69% 3.68% 27.23% 5.65% Kinase Inhibitors ERLOTINIB 1 month … 83.90% 21.34% 6.19% 74.16% 5.28% 0.25% 27.61% 14.70% 28.13% 31.10% Kinase Inhibitors EVEROLIMUS 1 month … 28.13% 25.00% 92.61% 95.17% 4.55% 4.55% 27.27% 9.94% 24.43% 29.26% Kinase Inhibitors GEFITINIB 1 month

4. Data-Points-7-Tables1 (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/data-points-7-tables1.pdf
   May 29, 2025 - 229.x 230.x to 234.x 235.x to 238.x 239.x Biologic response modifiers Aldesleukin 1 month … 5.2 2.6 18.4 19.8 48.5 39.8 68.8 13.5 * 33.3 14.8 36.1 27.8 Biologic response modifiers BCG 1 month … 0.4 3.3 2.3 13.2 98.5 6.6 2.2 0.0 32.8 31.5 40.8 59.4 Biologic response modifiers Denileukin 1 month … months 0.2 2.7 24.8 83.9 21.3 6.2 74.2 5.3 0.3 27.6 14.7 28.1 31.1 Kinase inhibitors Everolimus 1 month … .x 210.x to 229.x 230.x to 234.x 235.x to 238.x 239.x Kinase inhibitors Gefitinib 1 month

5. Data-Points-7-Tables (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/data-points-7-tables.pdf
   May 29, 2025 - 229.x 230.x to 234.x 235.x to 238.x 239.x Biologic response modifiers Aldesleukin 1 month … 5.2 2.6 18.4 19.8 48.5 39.8 68.8 13.5 * 33.3 14.8 36.1 27.8 Biologic response modifiers BCG 1 month … 0.4 3.3 2.3 13.2 98.5 6.6 2.2 0.0 32.8 31.5 40.8 59.4 Biologic response modifiers Denileukin 1 month … months 0.2 2.7 24.8 83.9 21.3 6.2 74.2 5.3 0.3 27.6 14.7 28.1 31.1 Kinase inhibitors Everolimus 1 month … .x 210.x to 229.x 230.x to 234.x 235.x to 238.x 239.x Kinase inhibitors Gefitinib 1 month

6. Cannabis-2023-Surv-Rep-4-Table-E-5 (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2023-surv-rep-4-table-E-5.xlsx
   January 01, 2023 - B Mean mg/week at 3 month followup THC: 93.29 (SD 228.12) vs. … C Pain, VAS score (scale 0-10; median, IQR) 1 month: 7.00 (5.00-8.00) vs. 5.50 (3.00-6.75) vs. 6.00 ( … C: 1.36 (95% CI 0.51 to 3.65) MPQ2-SF (scale 0-10; median, IQR) 1 month: 3.67 (2.32-4.96) vs. 2.55 ( … C BPI-Interference score (scale 0-10; median, IQR) 1 month: 5.86 (3.64-7.36) vs. 5.14 (2.21-5.93) vs. … B EQ-5D-5L composite score (scale <0-1; median, IQR) 1 month: 0.54 (0.31-0.65) vs. 0.74 (0.59-0.77) 3

7. Cannabis-2022-Surv-Rep-4-Table-F5 (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-2022-surv-rep-4-table-F5.xlsx
   January 01, 2022 - B Mean mg/week at 3 month followup THC: 93.29 (SD 228.12) vs. … C Pain, VAS score (scale 0-10; median, IQR) 1 month: 7.00 (5.00-8.00) vs. 5.50 (3.00-6.75) vs. 6.00 ( … C: 1.36 (95% CI 0.51 to 3.65) MPQ2-SF (scale 0-10; median, IQR) 1 month: 3.67 (2.32-4.96) vs. 2.55 ( … C BPI-Interference score (scale 0-10; median, IQR) 1 month: 5.86 (3.64-7.36) vs. 5.14 (2.21-5.93) vs. … B EQ-5D-5L composite score (scale <0-1; median, IQR) 1 month: 0.54 (0.31-0.65) vs. 0.74 (0.59-0.77) 3

8. Cer-265-Radiation-Bone-Disease-Addendum-App (xls file)
   effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-265-radiation-bone-disease-addendum-app.xlsx
   May 29, 2025 - cannot be premedicated for the use of contract dye N randomized: 353 N analyzed: 339 Attrition 1 month … Pain - index vertebra only, mean change from baseline (SD) Baseline: 6.06 (2.61) vs. 5.88 (2.41) 1 month … 3.07 (3.50) vs. -3.85 (2.56) 12 months: -3.34 (3.25) vs. -3.18 (3.23) NRS Pain Response, % (n/N) 1 month … 64% (25/39) 12 months: 57.6% (34/59) vs. 55.3% (21/38) Cumulative NRS Pain Response, % (n/N NR) 1 month … 2: 2 vs. 2 Grade 3: 0 vs. 0 Grade 4: 0 vs. 0 Grade 5: 0 vs. 0 Government Fair NRS Pain Response (1 month

9. Standardized Library of Asthma Outcome Measures (pdf file)
   effectivehealthcare.ahrq.gov/sites/default/files/wysiwyg/white-paper-library-asthma.pdf
   April 01, 2019 - Reported in 12-month intervals. • Patient scores (as opposed to ‘controlled’ vs. … Reported in 12-month intervals. • Patient scores (as opposed to ‘controlled’ vs. … The goal is to have 2 measurements in 12-month period. … Two measurements within a 24-month period is also acceptable, if two measurements within 12 months … Counted as number of events per patient in a 12-month reporting period.

10. Cer-250-Cannabis-2025-Surv-Rep-Update-Table-E5 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2025-surv-rep-update-table-e5.xlsx
    January 01, 2025 - B Mean mg/week at 3 month followup THC: 93.29 (SD 228.12) vs. … C Pain, VAS score (scale 0-10; median, IQR) 1 month: 7.00 (5.00-8.00) vs. 5.50 (3.00-6.75) vs. 6.00 ( … C: 1.36 (95% CI 0.51 to 3.65) MPQ2-SF (scale 0-10; median, IQR) 1 month: 3.67 (2.32-4.96) vs. 2.55 ( … C BPI-Interference score (scale 0-10; median, IQR) 1 month: 5.86 (3.64-7.36) vs. 5.14 (2.21-5.93) vs. … B EQ-5D-5L composite score (scale <0-1; median, IQR) 1 month: 0.54 (0.31-0.65) vs. 0.74 (0.59-0.77) 3

11. Cer-250-Cannabis-2024-Surv-Rep-Update-Table-E5 (xls file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-250-cannabis-2024-surv-rep-update-table-e5.xlsx
    January 01, 2024 - B Mean mg/week at 3 month followup THC: 93.29 (SD 228.12) vs. … C Pain, VAS score (scale 0-10; median, IQR) 1 month: 7.00 (5.00-8.00) vs. 5.50 (3.00-6.75) vs. 6.00 ( … C: 1.36 (95% CI 0.51 to 3.65) MPQ2-SF (scale 0-10; median, IQR) 1 month: 3.67 (2.32-4.96) vs. 2.55 ( … C BPI-Interference score (scale 0-10; median, IQR) 1 month: 5.86 (3.64-7.36) vs. 5.14 (2.21-5.93) vs. … B EQ-5D-5L composite score (scale <0-1; median, IQR) 1 month: 0.54 (0.31-0.65) vs. 0.74 (0.59-0.77) 3

12. The Use of Conjoint Analysis to Elicit Patient Preferences in Selecting Treatment Endpoints (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/mcda-johnson.pdf
    August 27, 2012 - , 5-month, and 10-month progression-free survival rates and chance of liver failure (no data points) … Slide 15 Maximum Acceptable Risk Calculation Renal Cell Carcinoma Image: Bar chart showing 3 month … , 5-month, and 10-month progression-free survival rates and chance of liver failure (no data points) … Slide 16 Maximum Acceptable Risk Calculation Renal Cell Carcinoma Image: Bar chart showing 3 month … , 5-month, and 10-month progression-free survival rates and chance of liver failure (no data points)

13. Executive summary_Comparative Effectiveness Review No. 270: Behavioral Interventions for Migraine Prevention (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-270-bimp-executive-summary.pdf
    May 01, 2024 - CI] -0.4 to -1.8, SOE: low), or relaxation training (pooled effect from 13 trials, -1 migraine day/month … 0.4 to -1.7; SOE: low), or mindfulness- based treatment (pooled effect from 5 trials, -1 migraine day/month … training may result in higher migraine attack frequency than propranolol (1 trial, 1.40 migraine days/month … frequency than a combination of CBT and relaxation training (1 trial, difference in migraine days/month … sleep modification in reducing headache frequency at 6-week followup (about 7 fewer migraine attacks/month

14. Behavioral Programs for Type 1 Diabetes Mellitus: Current State of the Evidence (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetes-behavior-programs_clinician-2016.pdf
    January 01, 2016 - More evidence is needed to determine if the reduction in HbA1c can be sustained at a 12-month or longer … Behavioral program vs. usual care HbA1c End of intervention† 16 1155 ↔ −0.11 (−0.33 to 0.11) ��� 6-month … followup 12 1463 ↓ −0.31 (−0.47 to −0.15)†† ��� 12-month followup 7 1333 ↔ −0.22 (−0.49 to 0.05) �� … vs. active control§ HbA1c End of intervention 4 566 ↔ −0.32 (−0.78 to 0.14) ��� 6-month followup 4 … † Outcomes were measured at ≤1 month after the intervention; the duration of the interventions ranged

15. Evidence-based Practice Center Systematic Review Protocol (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/alternative-payment-models-protocol.pdf
    December 16, 2024 - Key outcomes for key question 2 (cost savings) are: average Medicaid expenditure per month, behavioral … payment" OR "per member per month payments" OR "Medicare shared savings program" OR "Medicare Shared … payment") OR title: ("per member per month payments") OR title: ("Medicare shared savings program") … payment")) OR (abstract: ("per member per month payments")) OR (abstract: ("Medicare shared savings … payment” OR “per member per month payments” OR “Medicare shared savings program” OR “Medicare Shared

16. Glasgow.Presentation (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/interactive_media_glasgow_presentation.pdf
    January 01, 2009 -  website  usage  based  on  the  number  of  logons  per   participant  per  month …   • When  a  Web  site  offers  peer  support,  Web  site  logons  are:   o Month …  1-­‐3:  18.7  times   o Month  4-­‐6:  13.2  times   o Month  7-­‐10:  6.7  times …  1-­‐1:  9.4  times   o Month  4-­‐6:  5.1  times   o Month  7-­‐10:  3.6  times …   • Maintenance  (Individual  Level)  /  At  a  6-­‐month  follow-­‐up,  there  

17. Template for Draft Reports (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cad-pci-bypass_appendixes.pdf
    October 06, 2006 - Survival 1 month 5.092 0.242 107.297 0.295 110 / 110 108 / 110 MASS-II Survival 1 month 1.010 0.288 … Survival 1 month -0.006 -0.014 0.002 0.150 484 / 488 499 / 500 Toulouse Survival 1 month 0.000 -0.036 … month 0.000 -0.038 0.038 1.000 50 / 50 50 / 50 Seoul-Hong Survival 1 month -0.003 -0.039 0.034 0.891 … 108 / 110 106 / 110 MASS MI 1 month 0.507 0.045 5.724 0.583 70 / 72 69 / 70 MASS-II MI 1 month 1.010 … MI 1 month 1.352 0.292 6.255 0.700 73 / 76 72 / 76 Seoul-Kim MI 1 month 0.490 0.043 5.582 0.565 48 /

18. Clopidogrel after Drug-Eluting Stent Implantation: Is current practice sufficient (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/pdf/stent-clopidogrel-practice_research.pdf
    March 01, 2009 - clopidogrel use (yes or no) and 12 month clopidogrel use (yes or no)(Figures 1A and 1B). … Similarly, patients who were event-free at 12 months and completed the 12-month follow-up contact, … For the 12-month landmark analysis, patients with PCI procedures occurring after July 31, 2004 were … Unadjusted and adjusted 24-month outcomes based on 6-month patient-reported clopidogrel use Number … Unadjusted and adjusted 24-month outcomes based on 12-month patient-reported clopidogrel use Number

19. Disposition of Comments Report for Outpatient Case Management for Adults With Medical Illness and Complex Care Needs (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/case-management_disposition-comments.pdf
    January 01, 2013 - Source: www.effectivehealthcare.ahrq.gov Published Online: Month XX, 20XX 2 Commentator & Affiliation … Source: www.effectivehealthcare.ahrq.gov Published Online: Month XX, 20XX 3 Commentator & Affiliation … Source: www.effectivehealthcare.ahrq.gov Published Online: Month XX, 20XX 4 Commentator & Affiliation … Source: www.effectivehealthcare.ahrq.gov Published Online: Month XX, 20XX 5 Commentator & Affiliation … But unless they Source: www.effectivehealthcare.ahrq.gov Published Online: Month XX, 20XX 30

20. Executive Summary_Comparative Effectiveness Review No. 261_Postpartum Care up to 1 Year After Pregnancy: A Systematic Review and Meta-Analysis (pdf file)
    effectivehealthcare.ahrq.gov/sites/default/files/related_files/cer-261-postpartum-care-executive-summary.pdf
    June 01, 2023 - and 3 to 6 months and of exclusive breastfeeding at 1 month but with comparable rates of exclusive … and 1 NRCS) is probably associated with higher rates of any breastfeeding at 6 months but not at 1 month … no peer support, peer support was probably associated with higher rates of any breastfeeding at 1 month … to 6 months (summary ES 1.22, 95% CI 1.06 to 1.41; 4 studies) and of exclusive breastfeeding at 1 month … and 3 to 6 months and of exclusive breastfeeding at 1 month but comparable 6 rates of